A randomized trial of bevacizumab for newly diagnosed glioblastoma
about
Antiangiogenic therapy for high-grade gliomaGliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature reviewHigh-grade glioma management and response assessment-recent advances and current challengesChallenges of Using High-Dose Fractionation Radiotherapy in Combination TherapyTherapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolveImmune Evasion Strategies of GlioblastomaConcurrent therapy to enhance radiotherapeutic outcomes in glioblastomaA Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015Stereotactic Radiosurgery for GlioblastomaVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideAdvances in the treatment of newly diagnosed glioblastomaTherapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future directionBevacizumab for glioblastomaDevelopment of targeted therapies in treatment of glioblastomaRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsRisk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-AnalysisCurrent trends in the surgical management and treatment of adult glioblastomaTargeting Aggressive Cancer Stem Cells in GlioblastomaConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateBevacizumab in Japanese patients with malignant glioma: from basic research to clinical trialG protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenuesNF-κB and STAT3 in glioblastoma: therapeutic targets coming of ageCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsTargeted molecular therapies against epidermal growth factor receptor: past experiences and challengesImmunotherapy advances for glioblastomaMedical management of brain tumors and the sequelae of treatment.Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapyCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusPolymeric drug delivery for the treatment of glioblastomaEphs and Ephrins in malignant gliomasContemporary murine models in preclinical astrocytoma drug developmentTo what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Therapeutic Potential of Curcumin for the Treatment of Brain TumorsImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Prospects of immune checkpoint modulators in the treatment of glioblastomaGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsWhat next for newly diagnosed glioblastoma?
P2860
Q24193485-5E1614C9-1A3F-4036-8DAE-8D21F6812C57Q26739012-BAB9567F-231E-4490-9768-266E3E9EF63BQ26740664-492F0552-199F-4FD7-8A7D-0D979AB32FA8Q26742107-2D27F0B3-D9A3-4B8D-AE88-0F9B8FA90796Q26764947-EA2E0B9C-9048-47EA-B07B-D7E9353D8506Q26765855-B2F4DD55-773D-4D43-A144-6CA18FFECF6AQ26767169-A37C0096-9126-45B8-A7E2-D3B212014B25Q26767359-DD874C5D-511A-4CB5-B964-D22A5D484972Q26768680-B99AF8B1-BF84-4C82-9525-20193D28D596Q26770678-41BC323A-464C-405B-9DD0-A2DEA659537FQ26773514-95099E1D-5732-4DF3-9B08-9931478EC801Q26774717-39DF98F1-25D4-4CEF-85C8-1D1FA848E0D4Q26776307-9F848EB8-B9A3-4047-B4FB-9993A8A70F11Q26778787-E4995CA8-3CD8-4CC8-B791-D0C36835BAE3Q26779221-20327A6D-B075-4075-8D28-B359AE096447Q26783779-21681BC4-39C6-4087-A754-7FDDC50A6B4CQ26799854-BA1559F6-ED05-41E0-AEC1-22433468A195Q26799983-75405FD4-7931-4514-8909-6240D441386DQ26801351-3CDBEF2F-3446-4492-826D-4ACCA848CB31Q26822717-5DAEF316-7B30-4EB8-A32E-67017382AA2AQ26824777-D6B7AD23-BCB1-4F4D-B535-474D51C676E5Q26825769-9FAE10D4-2282-4E2B-929F-669D33D42859Q26830388-E8D1559B-D7BB-4E0A-98C0-0154B0CA55B8Q26853308-824ADFB9-BE97-4CEB-AFE6-196F1254696DQ26862516-48FD5245-4505-457A-B832-EAE41301A9A1Q26866513-CF276FB5-9F21-4FE4-A34A-833A9097B4DCQ26992174-04748801-FBCB-4DB3-8CCC-B50317D6B141Q26998111-6B0F5B12-04C3-48CB-BF83-6A2314151608Q27001560-28D52525-9B04-4160-8030-CD904467FD72Q27010046-94483200-D2DE-4112-AC1A-B240019D37EEQ27015780-83273B6F-D291-4451-B2DA-7298969EE5A5Q27026937-53AA4842-6384-4DF8-8469-B8215A5285E9Q27028189-5EC3AC8C-4BF7-486B-9047-1C756605EE42Q27310843-D9AEA3B3-AFAC-4BB4-B2E6-B26CDB21C2ADQ27853219-06A2F03E-1F53-4EDE-B9F2-9A32A9FBBAD3Q28071572-87AE3155-9656-4323-8126-8BDC2DA48EE2Q28078539-468674B7-396D-4BAB-8F21-CEF3331CA1BAQ28081371-4BF0C78D-36C8-48CA-B031-703F90B41BAFQ28082603-8A2ABBE8-10CA-4D87-B439-1B00CDA62CC6Q28086839-86D08A47-8924-45A1-9923-3D1EE1A81BE6
P2860
A randomized trial of bevacizumab for newly diagnosed glioblastoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized trial of bevacizumab for newly diagnosed glioblastoma
@ast
A randomized trial of bevacizumab for newly diagnosed glioblastoma
@en
type
label
A randomized trial of bevacizumab for newly diagnosed glioblastoma
@ast
A randomized trial of bevacizumab for newly diagnosed glioblastoma
@en
prefLabel
A randomized trial of bevacizumab for newly diagnosed glioblastoma
@ast
A randomized trial of bevacizumab for newly diagnosed glioblastoma
@en
P2093
P2860
P50
P356
P1476
A randomized trial of bevacizumab for newly diagnosed glioblastoma
@en
P2093
Arnab Chakravarti
David G Brachman
David Schiff
Deborah T Blumenthal
Erik P Sulman
Howard Colman
Ivo W Tremont-Lukats
James J Dignam
Jeffrey S Wefel
Kenneth D Aldape
P2860
P304
P356
10.1056/NEJMOA1308573
P407
P577
2014-02-01T00:00:00Z